FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to neurology, and can be used in treating the patients with multiple sclerosis. That is ensured by infusion of rituximab in a dose 1 g followed by introduction of mitoxantrone in a dose 20 mg and another infusion of rituximab in a dose 1 g 13-15 days later. A common preanaesthetic medication precedes infusion of rituximab.
EFFECT: method ensures fast therapeutic effect and prolonged remission in all forms of multiple sclerosis without a concomitant therapy, including chemotherapy.
1 ex, 11 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING MULTIPLE SCLEROSIS IN CHILDREN | 2015 |
|
RU2596792C1 |
| METHOD OF TREATING MULTIPLE SCLEROSIS AND OTHER SYSTEMIC AUTOIMMUNE DISEASES | 2015 |
|
RU2600160C1 |
| METHOD OF THERAPY OF REMITTENT MULTIPLE SCLEROSIS | 2012 |
|
RU2523058C2 |
| METHOD FOR DETERMINING PATHOLOGICAL PROCESS ACTIVITY IN PATIENTS WITH MULTIPLE SCLEROSIS | 2016 |
|
RU2613908C1 |
| SCHEMES AND METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS, USING OFATUMUMAB | 2017 |
|
RU2782069C2 |
| REGIMEN AND METHODS FOR MULTIPLE SCLEROSIS TREATMENT USING OFATUMUMAB | 2017 |
|
RU2749951C2 |
| METHOD OF PATHOLOGICAL PROCESS ACTIVITY DETERMINING IN PATIENTS WITH MULTIPLE SCLEROSIS | 2019 |
|
RU2694614C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF CNS ORGANIC LESIONS IN CHILDREN DURING THE ACUTE PERIOD | 2017 |
|
RU2648215C1 |
| METHOD OF TREATING MULTIPLE SCLEROSIS | 2005 |
|
RU2384345C2 |
| PEPTIDE FROM THE COMPOSITION OF THE IMMUNOGLOBULIN HUMAN HEAVY CHAIN, SUITABLE FOR TREATMENT OF MULTIPLE SCLEROSIS | 2016 |
|
RU2646817C1 |
